Abstract Human milk oligosaccharides (HMOs), though non-nutritive to the infant, shape the intestinal microbiota and protect against pathogens during early growth and development. Infant formulas with added galactooligosaccharides have been developed to mimic the beneficial effects of HMOs. Premature infants have an immature immune system and a leaky gut and are thus highly susceptible to opportunistic infections. A method employing nanoflow liquid chromatography time-of-flight mass spectrometry (MS) is presented to simultaneously identify and quantify HMOs in the feces and urine of infants, of which 75 HMOs have previously been fully structurally elucidated. Matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance MS was employed for highresolution and rapid compositional profiling. To demonstrate this novel method, samples from mother-infant dyads as well as samples from infants receiving infant formula fortified with dietary galacto-oligosaccharides or probiotic bifidobacteria were analyzed. Ingested oligosaccharides are demonstrated in high abundance in the infant feces and urine. While the method was developed to examine specimens from preterm infants, it is of general utility and can be used to monitor oligosaccharide consumption and utilization in term infants, children, and adults. This method may therefore provide diagnostic and therapeutic opportunities. 
Introduction
Human milk oligosaccharides (HMOs) possess no nutritive value for the infant and yet are found at high concentrations in breast milk, typically around 5-23 g/L [1] [2] [3] . These unbound oligosaccharides are beneficial to the infant in at least two ways. First, HMOs are non-digestible by the host and therefore reach the colon intact, where they act as prebiotics to selectively stimulate the growth of beneficial bacteria such as Bifidobacteria and Lactobacilli, resulting in the establishment of a healthy gut microbiota [2, 4] . Second, HMOs act as decoys, competitively binding to pathogens and preventing bacterial adhesion to epithelial cells [5, 6] . Preliminary data suggest a role for HMOs in brain development [7] and in leukocyte adhesion and platelet-neutrophil interactions [3] .
Five monosaccharide residues, namely: D-glucose (Glc), D-galactose (Gal) , N-acetylglucosamine (GlcNAc), L-fucose (Fuc), and sialic acid (N-acetyl neuraminic acid (Neu5Ac)), serve as the building blocks of HMOs. Whereas only one type of sialic acid residue is present in humans, both Neu5Ac and Neu5Gc are found in other species. These unbound oligosaccharides, commonly bearing a lactose core (Galβ-1,4Glc) at the reducing end, can be elongated with up to 25N-acetyllactosamine repeat units (Galβ-3/4GlcNAc).
The polylactosamine backbone can be sialylated in α2-3 and/or α2-6 linkages and/or fucosylated in α1-2, α1-3, and/or α1-4 linkages [3] . This heterogeneity in composition, specificity of linkages, variability in elongation, and intricacy in branching result in tremendous heterogeneity with over 200 HMOs identified in human breast milk [8] .
Unsurprisingly, identification of human milk oligosaccharides remains a formidable challenge. Several analytical techniques have been used to characterize and quantitate HMOs, including mass spectrometry (MS), nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, high pH anion-exchange chromatography, and capillary electrophoresis [9] [10] [11] [12] [13] .
Analysis of HMOs in term breast milk is routinely performed in our laboratory using nano-liquid chromatography chip/time-of-flight mass spectrometry (nano-LC chip/TOF MS) and matrix-assisted laser desorption/ionization Fourier transform-ion cyclotron resonance (MALDI FT-ICR) MS [9, 14, 15] . Mass spectrometry has been widely used for the analysis of bound and unbound oligosaccharides and has led to promising markers for several diseases [9, [16] [17] [18] . While FT-ICR MS provides exceptional mass accuracy at few parts per million (ppm) with extremely high mass resolution and has been extensively and successfully used in complex samples, nano-LC chip/TOF MS offers an orthogonal dimension of retention time and accurate mass, making it possible to separate isomeric HMOs, with and without sialic acids, in a single chromatographic separation. These two techniques, when combined with IRMPD and CID (collision-induced dissociation) tandem mass Fig. 1 Workflow of the analysis of human milk oligosaccharides from biological samples of motherinfant dyads. *HMO library from [23, 24] spectrometry (MS/MS), provide invaluable information on HMO structural elucidation [10, 12, 19] .
Early attempts to identify oligosaccharides in infant urine by MS showed only minimal differences between human milk-fed and formula-fed premature infants [20] . HMOs have been identified in the urine of nursing infants by administering 13 C-labeled galactose to nursing mothers followed by analysis of infant urine by isotope ratio-MS [21, 22] . A previous report identified HMOs in urine and feces of breast-fed infants but not formula-fed infants using MS [6] . However, these methods monitored only a small number of oligosaccharides, making it difficult to make extensive comparisons between milk, feces, and urine.
In this study, we report a novel rapid high-throughput method for the comprehensive analysis of HMOs in milk, feces, and urine samples, using nano-LC chip/TOF MS and MALDI FT-ICR MS. Feces samples were collected from diapers of premature infants. Rayon balls soaked in urine, but not contaminated with feces, were collected from diapers of premature infants. All samples were stored at −80°C until analysis.
Sample preparation for milk Thawed milk (500 uL) was centrifuged for 30 min at 4°C.
Sample preparation for feces Feces samples were thawed and homogenized prior to analysis. Nanopure water was added to the sample, and the mixture was left in the shaker overnight at 4°C. The mixture was then centrifuged at 4,000×g for 30 min at 4°C.
Sample preparation for urine One to three rayon balls were immersed in nanopure water, and the mixture was left in the shaker overnight at 4°C. Urine was extracted from the rayon balls using a 60 mL syringe. The volume was reduced to 1-3 mL using a centrifugal evaporator, and the mixture was centrifuged at 4,000×g for 30 min at 4°C. This approach was adopted to avoid irritation to premature skin that accompanies attachment of an adherent plastic bag to the perineum. Rayon balls were chosen to avoid the hexose polymer peaks observed by MALDI FT-ICR MS analysis in water-immersed cotton balls (no MS peaks were seen with water-immersed rayon balls).
Extraction, reduction, and purification of HMOs in milk, feces, and urine HMOs were extracted, reduced, and purified as described previously [9, 14, 23] . Four volumes of chloroform/methanol (2:1v/v) were added to the decanted liquid, and the mixture was centrifuged at 4,000×g for 30 min at 4°C. The upper layer was carefully transferred. Two volumes of ethanol were added, and the mixture was left at 4°C overnight and then centrifuged for 30 min at 4°C. The supernatant solution was evaporated to dryness using a centrifugal evaporator. HMOs were reduced to the alditol form by adding sodium borohydride and incubating at 65°C for 1 h. The HMOs were desalted and purified via twostep solid-phase extraction (SPE) using C8 reverse-phase (Supelco, Bellefonte, PA) and graphitized carbon (Alltech, Deerfield, IL) cartridges. C8 cartridges were conditioned with two bedfuls of acetonitrile (ACN) followed by two bedfuls of nanopure water. The HMOs were loaded onto the C8 cartridge, and the flow-through was collected and subsequently loaded on a preconditioned PGC cartridge. PGC cartridges were conditioned using two bedfuls of 80 % aqueous ACN with 0.1 % trifluoroacetic acid (TFA, v/v) and four bedfuls of nanopure water. After loading the sample onto the PGC cartridge, the cartridge was washed with four bedfuls of nanopure water to remove the salts. The desalted and purified HMOs were eluted using 20 % aqueous ACN and 40 % aqueous ACN with 0.05 % TFA, evaporated to dryness, and reconstituted with nanopure water prior to MS analysis. The workflow for analysis of fecal and urine HMOs excreted by preterm infants is outlined in Fig. 1 . Mass spectrometry analysis and determination of HMO structures HMOs in milk, feces, and urine were analyzed by MALDI FT-ICR MS (Varian ProMALDI) and nano-LC chip/TOF MS (Agilent 6200 Series HPLC chip/TOF-MS).
The FT-ICR MS is equipped with an external source ProMALDI (Varian, Palo Alto, CA), a pulsed Nd:YAG laser operating at 355 nm and a 7.0 Tesla magnet. External calibration was performed using malto-oligosaccharides [24] , Table 3 Quantitation of HMOs in milk, feces, and urine of a mother-infant dyad analyzed by nano-LC chip/TOF MS allowing mass accuracy of 10 ppm or better. DHB (2,5-dihydroxy-benzoic acid) was used as a matrix (5 mg/100 μL in 50 % ACN/H 2 O) for both positive and negative modes. Sodium chloride (0.01 M in 50 % ACN/H 2 O) was used as a cation dopant for the positive ion mode. The HMO sample, NaCl, and DHB were spotted on a 100-well stainless steel plate in 1:0.5:1 ratio, respectively. The sample was dried in the vacuum chamber before the plate was transferred to the ion Data files were filtered using Glycan Finder software (inhouse, written in Igor Pro 5.04B), which compares exact masses of theoretical oligosaccharides with the experimental accurate masses with a specified mass tolerance of 20 ppm. Manual inspection of the outputted peak list was performed to further remove false-positive entries.
Nano-LC chip/TOF MS analysis of HMOs was performed using a glycan HPLC micro chip as described previously [23] . Briefly, the micro chip has a 40 nL-enrichment column and a 43×0.075 mm ID analytical column, both packed with 5-um pore size porous graphitized carbon. Separation was performed using a binary gradient solvent system consisting of A, 3 % ACN in 0.1 % formic acid solution, and B, 90 % ACN in 0.1 % formic acid solution. The column was initially equilibrated and eluted at a flow rate of 0.4 uL for nanopump and 4 uL for capillary pump. One microliter of sample is then loaded to the column. A 65-min gradient was programmed as follows-2.5-20 min, Data were acquired using electrospray ionization (ESI)-TOF the positive ionization mode at a mass range of m/z 200-3,000. Mass correction was enabled automatically using several calibrant ions at a wide mass range (ESI-TOF Tuning Mix, Agilent Technologies, Santa Clara, CA). Data analysis was performed using Analyst QS 1.1 software, and the deconvoluted peaks were extracted using the molecular feature of the Agilent Mass Hunter software at 20 ppm error. Peaks were then confirmed, and retention times were corrected manually. The liquid chromatography-mass spectrometry (LC-MS) The infant was receiving unfortified mother's milk at the time of this collection ND not detected (i.e., below the level of detection) peak list was further submitted for analysis to a LC-MS Searcher software (in-house, written in Java) which assigns structures to a peak based on retention time and accurate mass [10, 19] . Around 2,000 spectra are inputted in this program per run, and with the HMO library, this program identifies the HMOs from all the scans based on retention times and m/z and outputs the intensity and the D/H ratios of the specific HMOs. The library of 45 neutral HMOs and 30 acidic HMOs was constructed using series of exoglycosidases and MS/MS analysis by Wu et al. [10, 19] . Each HMO is identified based on accurate mass and retention times.
To quantify the HMOs, we compared three methods: (1) using external standards relying primarily on peak areas and MS intensities, (2) using non-HMO internal standards such as oligomers of maltose (maltohexaose), and (3) employing deuterated internal HMO standards adapted from an earlier publication with some modifications [15] . The first two methods showed excessive variation in ionization response between the different types of oligosaccharides. The deuterated HMO internal standards resulted in a more linear quantitation over a larger dynamic range [15] .
Both the deuterated reference solution and sample solution were injected into the nano-LC chip/TOF MS and the H/D (hydrogen/deuterium) ratios were calculated by the LC-MS Searcher. In separate experiments, the deuterated reference solution was analyzed by the same instrument at several concentrations to determine the linear range. Similar standards were determined for solutions of lacto-N-tetraose at known concentrations. For the HMO standards, we utilized an HMO pool isolated from breast milk of several milk donors instead of the HMOs of the corresponding mother in a mother-preterm infant dyad because of the biological diversity in the Table 1 .
For de novo oligosaccharides, i.e., HMOs not in the HMO library, putative structures were obtained through collision-induced dissociation CID MS/MS using nano-LC chip/QTOF (Agilent 6520) [10, 19] .
Optimization of sample preparation procedure Feces and urine contain other components that interfere with the analysis of HMOs such as fats, proteins, salts, and other organic molecules [25] [26] [27] . Centrifugation and Folch extractions were performed to remove the fat layer and other insoluble solids [28] . The insoluble solids that settled at the bottom of the tube after centrifugation did not show the presence of HMOs upon MS analysis. Ethanol precipitation was performed to remove proteins and other organic residues [29, 30] . Subsequently, extracted HMOs were reduced from the aldehyde into the alditol form using sodium borohydride to prevent anomeric splitting of peaks during analysis by nano-LC chip/TOF MS [31] . The reduced HMOs were then purified by a two-step SPE: first using a C8 reverse-phase column to remove residual peptides and then using porous graphitized carbon column to desalt and purify the HMOs.
Results and discussion
Profiling HMOs in infant feces and urine Figure 2 shows the MALDI MS profile of the mother-infant dyad from feeding group 1 (mother's milk fortified with powdered human milk fortifier). The spectra show strong signals with excellent signal-to-noise ratio. The major HMO peaks are labeled; however, the baseline shows many more HMO signals that were readily differentiated. Most of the HMO structures in mother's milk are seen in the infant feces and urine. The pie charts correspond to the HMO distributions normalized against the total HMO abundance in the sample Fig. 6 Temporal nano-LC chip/TOF MS base peak chromatograms of the MS spectra shown in Fig. 5 . The pie charts show the distributions based on abundances normalized according to the total HMO abundance per sample using nano-LC chip/ TOF MS. Blue neutral nonfucosylated HMOs, red neutral fucosylated HMOs, green acidic non-fucosylated HMOs, purple acidic fucosylated HMOs obtained in the nano-LC chip/TOF MS run (data not shown). The MALDI MS results were used to observe the overall profile; however, for reproducibility and more accurate quantitation, results from the LC-MS analysis are monitored and presented. MALDI MS is significantly faster (<1 min compared with 60 min for LC-MS) and is used for rapidly determining sample quality. The two methods yielded consistent results. Note that this milk sample has a low percentage of fucosylated HMOs compared with that which is typical of milk from mothers delivering at term (approximately 60 %). This is consistent with our previous observation that HMO fucosylation is highly variable in women delivering preterm [23] .
The overall distribution of HMOs in milk, feces, and urine appear similar, with the non-fucosylated HMOs most abundant, followed by the fucosylated, sialylated, and then fucosylated and sialylated HMOs. Table 2 summarizes the five most abundant HMO compositions in milk, feces, and urine in a mother-preterm infant dyad analyzed by nano-LC chip/TOF MS. The HMO peak with m/z 732.3 is the most abundant in all three biological samples. However, the mono-fucosylated HMO peak with m/z 878.3 is abundant in both milk and urine but less abundant in feces, suggesting systemic absorption of this HMO. In contrast, the HMO peak with m/z 1,097.4, a neutral non-fucosylated HMO peak, is abundant in milk and feces but not in urine, suggesting that this HMO is not absorbed but passes mostly unchanged through the intestinal tract. The HMO peak with m/z 1,389.5 is abundant in milk but not in feces and urine suggesting deconstruction/consumption within the intestinal tract.
Lastly, sialylated HMO peaks are abundant in both the feces and urine but not in the milk, suggesting synthesis in the proximal intestine. Table 3 provides detailed quantitation of known HMO structures from a different mother-infant dyad (unfortified breast milk).
Effect of supplementation of human milk with concentrated pasteurized donor human milk The fecal HMOs of the premature infant in the second feeding group changed with addition of donor human milk. For the first 3 weeks, the infant received unfortified mother's milk. At the fourth week, the infant received mother's milk fortified with pasteurized concentrated donor human milk. By the sixth and seventh weeks, the supply of mother's own milk was decreasing and was partially replaced with donor human milk. Figure 3 shows the HMO profile of the preterm mother's milk and the concentrated donor human milk fortifier by MALDI FT-ICR MS. The donor human milk fortifier has more fucosylated HMO peaks (as indicated by the filled red circles). Note the presence of a difucosylated HMO with m/z 1,389, which is low in intensity in the mother's milk but high in the fortifier. Figure 4 shows the same samples analyzed by nano-LC MS. Approximately 70 HMOs were found in the premature mother's milk (Fig. 4a) and 100 in the donor milk fortifier (Fig. 4b) . The donor milk fortifier has higher abundances of the fucosylated oligosaccharides, as is typical of milk from mothers delivering at term. This side-by-side comparison demonstrates the differences between the two methods with MALDI MS providing a rapid overall profile and nano- LC MS providing increased reproducibility and more precise quantitation.
The mass spectral profiles of fecal HMOs by MALDI FT-ICR MS from the premature infant over the 7-week period are shown in Fig. 5 . Over time, the HMOs in feces begin to resemble that of the donor milk fortifier with the fucosylated oligosaccharides increasing in abundance. The increase is best monitored by the presence of m/z 1,389 (labeled peak). The peak rapidly rises from week 4 until it becomes the largest peak in the spectrum. The method demonstrates clearly the fecal HMOs originate more from the donor milk than from the mother's own milk. Figure 6 shows the same samples analyzed by nano-LC MS with a clear increase in fucosylated HMOs as the concentrated donor milk is added.
Fecal oligosaccharide profiling of preterm infants receiving prebiotic galacto-oligosaccharide (GOS) or probiotic B. lactis supplements Shown in Fig. 7 are the fecal oligosaccharide profiles of preterm infants receiving feeding regimen 3 (infant formula milk supplemented with GOS) and feeding regimen 4 (infant formula plus twice daily doses of B. lactis). As expected, no HMO peaks were observed in the feces of preterm infants fed exclusively infant formula milk (data not shown). Figure 7a shows the presence of GOS peaks in the fecal oligosaccharide profile of the infant, suggesting that at least a portion of the GOS dose passes through the intestinal tract undigested by the intestinal microbiota. Figure 7b , however, shows GOS peaks in the fecal profile of the infant receiving the probiotic B. lactis, which is known to be a non-consumer of HMOs. The presence of higher m/z GOS peaks was observed in several fecal samples of preterm infants receiving formula (that does not contain GOS) and supplemental B. lactis. The presence of larger GOS oligomers is unexpected and suggests the hypothesis that GOS may be synthesized by bacterial enzymes. The demonstrated method is ideal for testing this hypothesis.
In summary, we have demonstrated a method for highthroughput analysis of a broad range of HMOs and other oligosaccharides in infant feces and urine. Fecal HMOs represent structures that either survived passage through or were synthesized within the gastrointestinal tract. HMOs in the urine are absorbed from the intestinal tract and excreted and may be a marker of gut permeability and renal filtration. This method has the following advantages over existing methods: no need for maternal or infant ingestion of radiolabeled substances, high throughput, high mass accuracy and specificity, and structural identification of a broad range of oligosaccharides.
Premature infants are at high risk for opportunistic infections and nutrient deficiencies due to their immature intestinal tract and immune system. A method to monitor oligosaccharides passing through the gut intact (feces) or being absorbed into the bloodstream and then filtered (urine) may provide diagnostic and therapeutic opportunities. Furthermore, although this paper focuses on preterm motherinfant dyad samples, our method for the isolation and characterization of HMOs in feces and urine samples could also be used for term infants and even adults.
